Inquiry Basket
MC-Val-Cit-PAB-Auristatin E - CAS 2055896-77-8 Catalog number: BADC-00629
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
MC-Val-Cit-PAB-Auristatin E is a drug-linker conjugate for ADC with potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker MC-Val-Cit-PAB.
Category
ADCs Cytotoxin with Linkers
Product Name
MC-Val-Cit-PAB-Auristatin E
CAS
2055896-77-8
Catalog Number
BADC-00629
Molecular Formula
C68H108N11O13
Molecular Weight
1287.65
Ordering Information
| Catalog Number | Size | Price | Quantity |
|---|---|---|---|
| BADC-00629 | -- | $-- |
Description
MC-Val-Cit-PAB-Auristatin E is a drug-linker conjugate for ADC with potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker MC-Val-Cit-PAB.
Synonyms
MC Val Cit PAB Auristatin E
IUPAC Name
[4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-dimethylazanium
Canonical SMILES
O[C@@H](C1=CC=CC=C1)[C@@H](C)NC([C@H](C)[C@H]([C@@]2([H])N(CCC2)C(C[C@@H](OC)[C@@]([C@@H](C)CC)([H])N(C)C([C@H](C(C)C)NC([C@H](C(C)C)[N+](C)(C)CC3=CC=C(NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(CCCCCN4C(C=CC4=O)=O)=O)=O)=O)C=C3)=O)=O)=O)OC)=O
InChI
InChI=1S/C68H107N11O13/c1-16-44(8)59(52(91-14)39-56(83)77-38-24-28-51(77)62(92-15)45(9)63(85)71-46(10)61(84)48-25-19-17-20-26-48)76(11)67(89)58(42(4)5)75-66(88)60(43(6)7)79(12,13)40-47-30-32-49(33-31-47)72-64(86)50(27-23-36-70-68(69)90)73-65(87)57(41(2)3)74-53(80)29-21-18-22-37-78-54(81)34-35-55(78)82/h17,19-20,25-26,30-35,41-46,50-52,57-62,84H,16,18,21-24,27-29,36-40H2,1-15H3,(H7-,69,70,71,72,73,74,75,80,85,86,87,88,90)/p+1/t44-,45+,46+,50-,51-,52+,57-,58-,59-,60-,61+,62+/m0/s1
Shipping
-20°C (International: -20°C)
1.Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates
Staben LR, et al.
The reversible attachment of a small-molecule drug to a carrier for targeted delivery can improve pharmacokinetics and the therapeutic index. Previous studies have reported the delivery of molecules that contain primary and secondary amines via an amide or carbamate bond; however, the ability to employ tertiary-amine-containing bioactive molecules has been elusive. Here we describe a bioreversible linkage based on a quaternary ammonium that can be used to connect a broad array of tertiary and heteroaryl amines to a carrier protein. Using a concise, protecting-group-free synthesis we demonstrate the chemoselective modification of 12 complex molecules that contain a range of reactive functional groups. We also show the utility of this connection with both protease-cleavable and reductively cleavable antibody-drug conjugates that were effective and stable in vitro and in vivo. Studies with a tertiary-amine-containing antibiotic show that the resulting antibody-antibiotic conjugate provided appropriate stability and release characteristics and led to an unexpected improvement in activity over the conjugates previously connected via a carbamate.
Related Products
Historical Records: Dolastatin 10 | Top1 inhibitor 1 | Sulfo-PDBA-DM4 | Thailanstatin A | Hygrolidin | SJG-136 | Mertansine | Paclitaxel | DBA-DM4 | Diplacine | MC-Val-Cit-PAB-Auristatin E
